mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
24th Feb 2026, 12:30am (GMT)
Free, Online
Global mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
25th Feb 2026, 2:00pm (GMT)
Key Clinical Summary: Cancer Cachexia Update: Focus on Emerging Therapies
Updated 16 Dec 2025
Key Clinical Summary: Cancer Cachexia – The Patient Perspective
Key Clinical Summary: Cancer Cachexia: Multimodal Interventions and Multidisciplinary Management
Key Clinical Summary: Cancer Cachexia: Early Recognition and Comprehensive Care
Pediatric oncology
Posted by Armish Aziz, 19 Nov 2025, 3 comments
Hello, I'm Armish an aspiring pediatric oncologist .
If anyone is interested in it I would like to make a community driven by same passion.
ER+/HER2- metastatic breast cancer Options for treatment personalization based on resistance patterns and biomarkers
ER⁺/HER2⁻ Metastatic Breast Cancer: After CDK4/6: What’s Next?
Duration: 12m 59s
a month ago
ER⁺/HER2⁻ Metastatic Breast Cancer: Putting Biomarkers to Work
Duration: 14m 30s
Advances in Lung & GI Community Oncology 2025
29th Oct 2025, 10:30pm (GMT)
Advances in Lung & GI Community Oncology 2025: Biomarker testing in practice
Duration: 14m 4s
2 months ago
Advances in Lung & GI Community Oncology 2025: First-line personalisation & AE management
Duration: 10m 51s
Advances in Lung & GI Community Oncology 2025: The Patient Perspective
Duration: 10m 25s
Cancer Cachexia: Early diagnosis and multimodal strategies of care
Cancer Cachexia: Pharmacologic Management: Emerging Therapies
ER⁺/HER2⁻ Metastatic Breast Cancer: Latest Advances
Duration: 1hr 18m 5s
Personalizing Therapy in ER⁺/HER2⁻ Metastatic Breast Cancer via Biomarkers and Evidence-Based Decision-Making
Updated 17 Oct 2025
Optimize post-CDK4/6 sequencing in ER⁺/HER2⁻ mBC based on clinical and molecular resistance patterns
Added 17 Oct 2025
Differentiation of emerging endocrine therapies in ER⁺/HER2⁻ mBC based on MoA and clinical role
